Lucid Diagnostics

LUCDPre-clinical

Lucid Diagnostics is a publicly traded company (NASDAQ: LUCD) dedicated to preventing cancer deaths through early detection. Its core mission is to address the unmet need in screening for Barrett's Esophagus, the pre-cancerous condition leading to esophageal adenocarcinoma (EAC), a lethal cancer with rapidly increasing incidence. The company's integrated solution, EsoCheck and EsoGuard, provides a non-endoscopic, office-based method for targeted screening of at-risk patients, representing a significant advancement over the standard of care.

Market Cap

$163.9M

Employees

50-100

Focus

Biotech

LUCD · Stock Price

USD 1.2510.51 (-89.37%)

Historical price data

AI Company Overview

Technology Platform

Proprietary, two-component platform featuring EsoCheck, a non-endoscopic esophageal cell collection device, and EsoGuard, a bisulfite-converted next-generation sequencing (NGS) assay that detects DNA methylation biomarkers for Barrett's Esophagus and esophageal adenocarcinoma.

Funding History

Total raised: $65M

IPO$40MUndisclosedNov 19, 2021

Series A$25MPavilion CapitalJun 15, 2018

Opportunities

The primary growth opportunity lies in capturing a significant portion of the multi-billion dollar U.S.

market for Barrett's Esophagus screening, which is currently vastly underpenetrated.

Additional opportunities include expanding into surveillance of known BE patients, exploring international markets, and potentially applying the core methylation technology to other aerodigestive cancers.

Risk Factors

Key risks include slow physician adoption and commercial execution, failure to secure adequate and widespread insurance reimbursement, intense competition from established and emerging technologies, and the ongoing need for additional capital financing in a challenging market environment.

Competitive Landscape

Lucid competes directly with the invasive standard of care (endoscopy) and other non-endoscopic technologies, most notably Medtronic's Cytosponge. Its differentiation is based on its proprietary cell collection device and a DNA methylation-based NGS assay, which it positions as a highly specific and objective molecular alternative to cytology or immunohistochemistry-based tests.